TEMPO 3:4
2012
Tolvaptan Efficacy and Safety in Management of ADPKD and its Outcomes
In 1,445 patients with autosomal dominant polycystic kidney disease, tolvaptan slowed total kidney-volume growth compared with placebo.
Result
Primary endpoint: Annual rate of total kidney-volume increase
2.8% vs 5.5% per year (p<0.001); slower reciprocal-creatinine decline.
- Subtopic
- ADPKD
- Design
- Double-blind RCT over 3 years
- Relevance
- Important: one of several pillars.
- Cited in
- KDIGO 2025 ADPKD
- Source
- Torres VE, et al. N Engl J Med. 2012;367(25):2407-2418.doi 10.1056/NEJMoa1205511
Discussion & critique
First disease-modifying therapy for ADPKD; aquaretic side effects and idiosyncratic hepatotoxicity drove a 23% dropout.